Skip to main content
Logo
European Innovation Council
private sector

Osivax

Osivax Logo

Overview

Description

Osivax’ mission is to prevent globally impactful infectious diseases. Leveraging its unique oligoDOM® technology platform. The Company is developing a universal flu vaccine for both current and future influenza infections. OVX836 vaccine candidate is in Phase 2a clinical development.

Osivax is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. Osivax is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases. ​

Website
Invested amount

EUR 3 930 975

Founded

2017

Project
Country
  • France
Theme
  • Space